Truly Tumor-Specific antibodies

Partnering with biopharma to deliver tailored antibody solutions that drive therapeutic progress

All cancers have one thing in common -

a modification abundant in cancers but absent in healthy cells.

Healthy tissue

Tumor tissue

Combotopes' proprietary Antibody Discovery Platform generates antibodies with:

Tumor selectivity

High affinity

Flexibility

Why does it matter?

For Pharma:

  • Novel cancer targets

  • ADC, BsAb, BiTE, RI-mAbs..

  • Untouched IP space

For Patients:

  • Better treatment options

  • Reduced side-effects

  • Improved quality of life

What we deliever

Antibodies for novel tumor antigens with fast, cost-effective discovery and collaborative IP solutions

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN

〰️

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️

We offer an attractive win-win partnership business model

  • Upfront, and milestone payments tied to development and regulatory achievements

  • Minimum royalties and royalties based on product sales.

Crystal structure revealing how Combotope antibodies specifically binds cancer-specific Tn-glycoprotein epitopes

Leadership

  • Dr. Klas Ola Blixt

    CO-FOUNDER, INVENTOR, & CEO

    Ola is the inventor of the Combotope concept, with deep expertise in aberrant glycosylation, enabling cancer-specific antibody development. With over 20 years of research in chemical biology, glycoscience, and monoclonal antibodies, Ola has numerous highly cited publications (H=50) and patents, along with 15+ years of management experience.

  • Dr. Søren Nyboe Jakobsen

    CO-FOUNDER, COO

    Søren is the inventor or co-inventor of patents in molecular display, selection techniques, and T/B cell detection. He founded and led Tetramer Shop, acquired by 10x Genomics, and has developed foundational IP and products at biotech firms like Novo Nordisk, Nuevolution, Immudex, and 10x Genomics. With strong startup management and leadership experience, Søren has driven innovation in biotech.

Combotope Therapeutics ApS

Diplomvej 381

DK-2800 Kongens Lyngby

Denmark

Contact:

olablixt@combotope.com

Company registration (CVR) no. 44308266